Why the study?
What are the pharmacologic opportunities for improving prophylaxis of vasoocclusive disorders beyond aspirin?
What are the pharmacologic opportunities for improving prophylaxis of vasoocclusive disorders beyond aspirin?
This review highlights the potential for combination antithrombotic therapies to improve upon aspirin for the prophylaxis of vasoocclusive disorders, calling for future clinical trials.
No takes yet. Share an insight, caveat, or question.
Combination antithrombotic regimens merit trial evaluation for vasoocclusive prophylaxis; leaves open net benefit beyond aspirin.
Ritter et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: